JP2007502817A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502817A5
JP2007502817A5 JP2006523866A JP2006523866A JP2007502817A5 JP 2007502817 A5 JP2007502817 A5 JP 2007502817A5 JP 2006523866 A JP2006523866 A JP 2006523866A JP 2006523866 A JP2006523866 A JP 2006523866A JP 2007502817 A5 JP2007502817 A5 JP 2007502817A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
pharmaceutical salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006523866A
Other languages
English (en)
Japanese (ja)
Other versions
JP4754487B2 (ja
JP2007502817A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/024387 external-priority patent/WO2005019212A1/en
Publication of JP2007502817A publication Critical patent/JP2007502817A/ja
Publication of JP2007502817A5 publication Critical patent/JP2007502817A5/ja
Application granted granted Critical
Publication of JP4754487B2 publication Critical patent/JP4754487B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006523866A 2003-08-20 2004-08-18 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 Expired - Fee Related JP4754487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49653703P 2003-08-20 2003-08-20
US60/496,537 2003-08-20
PCT/US2004/024387 WO2005019212A1 (en) 2003-08-20 2004-08-18 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide

Publications (3)

Publication Number Publication Date
JP2007502817A JP2007502817A (ja) 2007-02-15
JP2007502817A5 true JP2007502817A5 (enExample) 2007-05-31
JP4754487B2 JP4754487B2 (ja) 2011-08-24

Family

ID=34216017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006523866A Expired - Fee Related JP4754487B2 (ja) 2003-08-20 2004-08-18 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
JP2011104435A Pending JP2011207886A (ja) 2003-08-20 2011-05-09 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011104435A Pending JP2011207886A (ja) 2003-08-20 2011-05-09 グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤

Country Status (12)

Country Link
US (3) US20070293423A1 (enExample)
EP (1) EP1658285B1 (enExample)
JP (2) JP4754487B2 (enExample)
CN (1) CN100398536C (enExample)
AT (1) ATE361294T1 (enExample)
AU (1) AU2004267044B8 (enExample)
BR (1) BRPI0413676B8 (enExample)
CA (1) CA2530983C (enExample)
DE (1) DE602004006279T2 (enExample)
ES (1) ES2286679T3 (enExample)
MX (1) MXPA06001916A (enExample)
WO (1) WO2005019212A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
HUE037147T2 (hu) 2005-07-08 2018-08-28 Ipsen Pharma Melanokortin-receptor ligandumai
WO2008027958A2 (en) * 2006-08-31 2008-03-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
BRPI0909947A2 (pt) 2008-06-09 2017-06-27 Palatin Technologies Inc '' peptídeo cíclico, composição farmacêutica, método de tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em seres humanos ou mamíferos não humanos, e, método de tratamento de condição que reage a alterações da função de receptor de melanocortina em seres humanos ou mamíferos não humanos''
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
US10357348B2 (en) * 2013-08-19 2019-07-23 Warren Matthew Leevy Fluid manifold
US20160244860A1 (en) * 2015-02-20 2016-08-25 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN105017136A (zh) * 2015-07-24 2015-11-04 陈吉美 一种2-溴-3-甲氧基吡啶的制备方法
BR112019016241A2 (pt) 2017-02-08 2020-04-07 Bayer Cropscience Ag derivados de triazol e seu uso como fungicidas
EP3580218A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
CN110267952A (zh) 2017-02-08 2019-09-20 拜耳公司 三唑硫酮衍生物
AU2018217749A1 (en) 2017-02-10 2019-08-01 Bayer Aktiengesellschaft Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
CN111793038B (zh) * 2019-04-08 2022-08-12 新发药业有限公司 一种取代噁唑化合物的环保制备方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2423709A (en) * 1947-07-08 X-aryl thiazole
US595503A (en) * 1897-12-14 Cross-clevis
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
US6211215B1 (en) * 1996-07-19 2001-04-03 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
DK1093819T3 (da) * 1997-02-07 2006-09-11 Emisphere Tech Inc Forbindelse og præparat til tilförsel af aktive midler
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
CN1338924A (zh) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 聚合物输送剂和输送剂化合物
JP4854855B2 (ja) * 1999-02-11 2012-01-18 エミスフェアー・テクノロジーズ・インク オキサジアゾール化合物及び活性剤をデリバリーするための組成物
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CZ20021570A3 (cs) 1999-11-05 2002-10-16 Emisphere Technologies, Inc. Fenylaminkarboxylové kyseliny a kompozice pro dodávání aktivních činidel
ES2298168T3 (es) 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
EP1246792B1 (en) 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT1299348E (pt) 2000-06-29 2008-05-12 Emisphere Tech Inc Compostos e composições para administração de agentes activos
IL154110A0 (en) * 2000-08-23 2003-07-31 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US6982278B2 (en) * 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
AU2002215218A1 (en) * 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Isoxazole derivatives
JP4148672B2 (ja) * 2000-11-17 2008-09-10 武田薬品工業株式会社 イソオキサゾール誘導体
HUP0302526A2 (hu) 2000-12-21 2003-11-28 Glaxo Group Limited Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
JP4248244B2 (ja) * 2001-02-14 2009-04-02 明治製菓株式会社 12、13位変換新規16員環マクロライド誘導体
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
AU2002305720A1 (en) * 2001-05-30 2002-12-09 Huening, Tracy, T. Piperazine pentanamide hiv protease inhibitors
CN1568187A (zh) * 2001-08-15 2005-01-19 Icos股份有限公司 2h-2,3-二氮杂萘-1-酮和其使用方法
US6969057B2 (en) 2001-10-30 2005-11-29 Illinois Tool Works Inc. Method and apparatus for adjusting and positioning air caps
AU2002367426A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Neurotrophic factor production/secretion accelerator
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
CA2487315A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
JP2004277397A (ja) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd 1,2−アゾール誘導体
WO2005000339A2 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005019184A1 (en) * 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide

Similar Documents

Publication Publication Date Title
JP2007502817A5 (enExample)
JP2005510563A5 (enExample)
JP2004536811A5 (enExample)
JP2005507872A5 (enExample)
JP2005507918A5 (enExample)
JP2006526031A5 (enExample)
JP2002543183A5 (enExample)
JP2009501177A5 (enExample)
JP2009501178A5 (enExample)
JP2011522789A5 (enExample)
JP2005511547A5 (enExample)
JP2008523126A5 (enExample)
JP2005053931A5 (enExample)
JP2007522220A5 (enExample)
JP2005112864A5 (enExample)
JP2008505194A5 (enExample)
JP2002501049A5 (enExample)
JP2010523476A5 (enExample)
JP2005539088A5 (enExample)
JP2009519243A5 (enExample)
JP2008534636A5 (enExample)
JP2007500753A5 (enExample)
JP2007510662A5 (enExample)
JP2005538089A5 (enExample)
JP2007500222A5 (enExample)